An Open-Label Study To Evaluate The Efficacy And Safety Of Revusiran In Patients With Transthyretin-Mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post Orthotopic Liver Transplant
Phase of Trial: Phase II
Latest Information Update: 30 May 2017
At a glance
- Drugs Revusiran (Primary)
- Indications Amyloid polyneuropathy
- Focus Therapeutic Use
- Sponsors Alnylam Pharmaceuticals
- 23 May 2017 Status changed from discontinued to completed.
- 18 Feb 2017 The trial has been completed in Spain.
- 12 Nov 2016 This trial was suspended in Spain.